Skip to main content

G1 Therapeutics, Inc.

GTHXDelisted Sep 18, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001560241

G1 Therapeutics, Inc. was delisted on Sep 18, 2024; its insiders filed their last Form 4 on Sep 18, 2024; 88 institutions reported holding it in 13F filings for Q2 2024, worth $45.5M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by G1 Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for G1 Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for G1 Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Muir Glenn PDirector0Sep 18, 20240
Murdock Terry LChief Operating Officer0Sep 18, 20240
Secor AliciaDirector0Sep 18, 20240
Nicholson Garry ADirector0Sep 18, 20240
Malik RajeshChief Medical Officer0Sep 18, 20240
Flowers Cynthia LouiseDirector0Sep 18, 20240
Avagliano MarkChief Business Officer0Sep 18, 20240
Bailey John E. (Jack) Jr.President and CEO0Sep 18, 20240
Perry AndrewChief Commercial Officer0Sep 18, 20240
Lee JacksDirector0Sep 18, 20240
Sharpless NormanDirector0Sep 18, 20240
Umstead John V.Chief Financial Officer0Sep 18, 20240
Thomas Monica R.Chief Legal & People Officer0Sep 18, 20240
Velleca Mark A.Director116,000Aug 10, 20230
Moses Jennifer K.CFO57,820Jan 5, 20230
Hanson James S.General Counsel41,087Jan 5, 20230
Deese Willie ADirector14,389Jun 24, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 8, 2024 (view filing)Jul 53 daysPerry AndrewChief Commercial OfficerSSale−1.34K$2.51−$3.36K−1.2%112.6K after
Jul 8, 2024 (view filing)Jul 53 daysMurdock Terry LChief Operating OfficerSSale−2.48K$2.51−$6.21K−1.9%128.0K after
Jul 8, 2024 (view filing)Jul 53 daysMalik RajeshChief Medical OfficerSSale−2.48K$2.51−$6.21K−1.5%159.3K after
Jul 8, 2024 (view filing)Jul 53 daysAvagliano MarkChief Business OfficerSSale−2.64K$2.51−$6.62K−1.1%242.0K after
Jul 8, 2024 (view filing)Jul 53 daysUmstead John V.Chief Financial OfficerSSale−527$2.51−$1.32K−0.3%187.7K after
Jul 8, 2024 (view filing)Jul 53 daysBailey John E. (Jack) Jr.President and CEOSSale−7.66K$2.51−$19.2K−1.4%549.7K after
May 24, 2024 (view filing)May 231 dayThomas Monica R.Chief Legal & People OfficerSSale−5.83K$4.27−$24.9K−5.0%109.8K after
May 15, 2024 (view filing)May 132 daysPerry AndrewChief Commercial OfficerSSale−8.15K$4.79−$39.0K−9.4%79.0K after
May 15, 2024 (view filing)May 132 daysUmstead John V.Chief Financial OfficerSSale−8.15K$4.79−$39.0K−5.1%153.2K after
May 15, 2024 (view filing)May 132 daysMurdock Terry LChief Operating OfficerSSale−8.15K$4.79−$39.0K−7.9%95.5K after
May 15, 2024 (view filing)May 132 daysMalik RajeshChief Medical OfficerSSale−8.15K$4.79−$39.0K−4.8%161.8K after
May 15, 2024 (view filing)May 132 daysAvagliano MarkChief Business OfficerSSale−8.15K$4.79−$39.0K−3.7%209.7K after
May 15, 2024 (view filing)May 132 daysBailey John E. (Jack) Jr.President and CEOSSale−37.3K$4.79−$178.5K−7.6%452.3K after
Mar 20, 2024 (view filing)Mar 182 daysUmstead John V.Chief Financial OfficerSSale−6.55K$3.02−$19.8K−5.0%123.9K after
Feb 13, 2024 (view filing)6:14 PM ETFeb 121 dayMalik RajeshChief Medical OfficerSSale−28.6K$4.62−$132.1K−14.4%169.9K after10b5-1
Jan 8, 2024 (view filing)Jan 3-45 daysLateUmstead John V.Chief Financial OfficerSSale−743$3.09−$2.30K−0.6%130.4K after3 lots
Jan 8, 2024 (view filing)Jan 3-45 daysLateMalik RajeshChief Medical OfficerSSale−3.74K$3.09−$11.5K−2.2%169.9K after3 lots
Jan 8, 2024 (view filing)Jan 35 daysLatePerry AndrewChief Commercial OfficerSSale−2.41K$3.12−$7.53K−2.7%87.1K after2 lots
Jan 8, 2024 (view filing)Jan 35 daysLateBailey John E. (Jack) Jr.President and CEOSSale−11.7K$3.12−$36.5K−2.3%489.6K after2 lots
Jan 8, 2024 (view filing)Jan 3-45 daysLateAvagliano MarkChief Business OfficerSSale−4.08K$3.09−$12.6K−3.3%117.8K after3 lots
Jan 8, 2024 (view filing)Jan 3-45 daysLateMurdock Terry LChief Operating OfficerSSale−3.74K$3.09−$11.5K−3.5%103.6K after3 lots
Jan 2, 2024 (view filing)Jan 2Same dayBailey John E. (Jack) Jr.President and CEOSSale−33.0K$3.27−$107.9K−7.6%400.6K after
Dec 13, 2023 (view filing)4:45 PM ETDec 112 daysMalik RajeshChief Medical OfficerSSale−33.8K$3.41−$115.5K−19.9%136.4K after2 lots10b5-1
Aug 10, 2023 (view filing)4:11 PM ETAug 82 daysVelleca Mark A.DirectorSSale−60.0K$2.00−$120.0K−34.1%116.0K after2 lots10b5-1
Jul 7, 2023 (view filing)Jul 52 daysPerry AndrewChief Commercial OfficerSSale−355$2.45−$869.75−0.6%55.9K after10b5-1
Jul 7, 2023 (view filing)Jul 52 daysMurdock Terry LChief Operating OfficerSSale−1.36K$2.45−$3.33K−1.9%70.1K after10b5-1
Jul 7, 2023 (view filing)Jul 52 daysMalik RajeshChief Medical OfficerSSale−1.36K$2.45−$3.33K−1.0%136.4K after10b5-1
Jul 7, 2023 (view filing)Jul 52 daysBailey John E. (Jack) Jr.President and CEOSSale−2.72K$2.45−$6.66K−0.6%433.6K after10b5-1
Jan 5, 2023 (view filing)Jan 4-51 dayMoses Jennifer K.CFOSSale−2.37K$5.53−$13.1K−3.9%57.8K after2 lots
Jan 5, 2023 (view filing)Jan 4-51 dayMurdock Terry LChief Operating OfficerSSale−2.37K$5.53−$13.1K−6.1%36.4K after2 lots
Jan 5, 2023 (view filing)Jan 41 dayPerry AndrewChief Commercial OfficerSSale−820$5.58−$4.58K−3.7%21.3K after
Jan 5, 2023 (view filing)Jan 4-51 dayMalik RajeshChief Medical OfficerSSale−2.37K$5.53−$13.1K−2.3%102.7K after2 lots
Jan 5, 2023 (view filing)Jan 4-51 dayHanson James S.General CounselSSale−2.37K$5.53−$13.1K−5.4%41.1K after2 lots
Jan 5, 2023 (view filing)Jan 3-42 daysBailey John E. (Jack) Jr.President and CEOSSale−37.6K$5.81−$218.6K−12.0%276.3K after2 lots
Oct 20, 2022 (view filing)4:05 PM ETOct 182 daysVelleca Mark A.DirectorSSale−15.0K$11.70−$175.5K−11.5%116.0K after
Sep 22, 2022 (view filing)4:40 PM ETSep 202 daysVelleca Mark A.DirectorSSale−20.0K$13.50−$270.0K−14.7%116.0K after
Sep 16, 2022 (view filing)4:31 PM ETSep 133 daysLateMalik RajeshChief Medical OfficerSSale−18.0K$15.71−$282.7K−19.7%73.2K after
Aug 18, 2022 (view filing)4:06 PM ETAug 162 daysVelleca Mark A.DirectorSSale−80.0K$12.64−$1.01M−40.8%116.0K after
Jul 6, 2022 (view filing)Jul 51 dayMurdock Terry LChief Operating OfficerSSale−648$5.17−$3.35K−3.0%20.9K after
Jul 6, 2022 (view filing)Jul 51 dayMalik RajeshChief Medical OfficerSSale−648$5.17−$3.35K−0.9%73.2K after
Jan 5, 2022 (view filing)Jan 5Same dayHanson James S.General CounselSSale−1.45K$10.61−$15.3K−5.4%25.6K after
Jan 5, 2022 (view filing)Jan 5Same dayMurdock Terry LChief Operating OfficerSSale−1.45K$10.61−$15.3K−6.3%21.6K after
Jan 5, 2022 (view filing)Jan 5Same dayMoses Jennifer K.CFOSSale−1.45K$10.61−$15.3K−3.9%35.6K after
Jan 5, 2022 (view filing)Jan 5Same dayMalik RajeshChief Medical OfficerSSale−1.45K$10.61−$15.3K−2.2%63.9K after
Jan 5, 2022 (view filing)Jan 5Same dayAvagliano MarkChief Business OfficerSSale−1.45K$10.61−$15.3K−6.3%21.6K after
Jan 5, 2022 (view filing)Jan 32 daysBailey John E. (Jack) Jr.President and CEOSSale−34.1K$10.41−$355.2K−12.8%233.2K after
Jul 15, 2021 (view filing)4:01 PM ETJul 13-152 daysVelleca Mark A.DirectorSSale−30.0K$19.01−$570.3K−33.0%61.0K after3 lots